We’re all about building
a healthier society
We believe that DNA testing can empower healthcare professionals and their patients. We understand the concerns that surround inherited genetic illness, cancer and serious health conditions and work to mitigate the risks and develop more targeted solutions. Our genetic screening and advisory services apply the latest technology and data analysis to assist in doctors and specialists providing effective treatments options.
Our Vision
We aim to be a leading global innovator in the biotechnology industry by continuously developing ground-breaking molecular diagnostic (MDx) technologies, increasing health awareness in society and inspiring future generations in order to achieve a healthier community with higher standard of living.
We are to be concerned with their health by striving ourselves toward “A step ahead for healthcare”.
Our Mission
We are dedicated to providing the public with the best preventive and the most precise disease diagnosis through the diligence of our devoted experts, the guarantee of our high-quality laboratory services, and the continuation of our innovative biotechnological advancement.
Proven Technology
Molecular diagnostics technology moves fast. Newer tests tend to be quicker, more revealing and more expensive. Older tests often cost less but may not be as informative. There is a valuable role for both. Our goal is to give medical professionals and patients the widest possible choice. Our technology includes cutting edge next-generation sequencing (NGS) and other frequently used methods such as RT-PCR and Sanger sequencing.
A Step Ahead With Technology
Personalized treatments are increasingly preferred when facing many diseases and conditions. Such treatments depend on finding and interpreting individual genetic information. However, this information is often complex and can overwhelm conventional data systems.
Pangenia’s advanced test platforms can rapidly process huge amounts of genetic information within a shorter time. Our analytical instruments utilize next-generation sequencing (NGS) technology which can meticulously screen sections of an individual’s genome to identify mutations. This can be hugely effective in designing personalized treatments. We also provide real-time PCR and Sanger sequencing test services to meet patients’ differing needs.
Next-Generation Sequencing (NGS)
NGS technology targets genes and mutations relevant to particular cancers. With significantly higher read length and read depth than traditional techniques, NGS allows us to sequence large genomic regions, providing comprehensive genetic profiles in a single efficient and cost-effective report. This form of testing helps identify rare somatic mutations which may have been misinterpreted as negative.
Real-time PCR
Real-time PCR testing allows us to analyze multiple targets simultaneously within a single reaction. This has a number of advantages, and can provide internal controls, lower reagent costs and preserve precious samples. Real-time PCR testing can provide reports in three to five days.
Our Team
Dr. Rebecca HK Lee
Assistant General Manager
Over 10+ years of experience in molecular diagnostics industry;
Former HKSTP fund assessment panelist;
Former HKUST research project fund assessment panelist;
Master of Philosophy at the University of Hong Kong;
PhD at the National Institute for Basic Biology, Japan;
Member of Hong Kong Society for Molecular Diagnostic Sciences Ltd
Dr. Alex Kiselyov
Chief Scientific Officer
Over two decades of drug discovery and development expertise in pharma and biotech companies including Amgen, ImClone/Lilly, deCODE, Genea Biocells;
diverse modalities in mid/late stages of clinical developments to treat oncology, CNS, metabolic and neuromuscular disorders with specific emphasis on rare diseases;
over 170 peer-reviewed publications and over 60 granted patents and patent applications
Francis Tam
Vice President, Sales and Marketing
Head of Sales & Marketing;
Board Member of numerous Biotechnology companies in Hong Kong and China;
Over 20 years of project management and sales marketing;
BSLA; EMIL; MBA
Simon Lownang
Director of Business Development
Extensive working experience in renowned international and locally listed companies;
Executive management roles and providing business consultancy to retail sales and marketing of luxury products in a global environment, public transport and private wealth management;
Holder of B.A.Sc degree in Chemical Engineering and M.B.A. (Professional Accounting) degree from University of Toronto.
Dr. Tyler Leung
Senior Manager
Biotechnology Scientist;
Former Program Manager, Project Planning and Execution Group, Hong Kong Applied Science and Technology Research Institute Company Limited (ASTRI);
PhD, The Hong Kong Baptist University
Dr. Patrick Law
Chief Scientist
Biochemistry Scientist;
Scientific Officer, The Chinese University of Hong Kong;
PhD, GradD, M.Phil., The Chinese University of Hong Kong
Dr. Kit S. Lam, MD
Scientific Advisor
Medical oncologist;
Distinguished Professor and Chair, Department of Biochemistry and Molecular Medicine, UC Davis Health School of Medicine;
Sue Jane Leung Presidential Chair in Cancer Research & Harold Albin Johnson Endowed Chair in Biomedical Research, UC Davis NCI-Designated Comprehensive Cancer Center;
PhD in Oncology, McArdle Laboratory for Cancer Research, University of Wisconsin;
MD, Stanford University School of Medicine
Dr. See-Ying Tam
Scientific Advisor
Currently Principal Investigator with the Department of Pathology, Dr. Tam joined Stanford University in 1999. He is also an Honorary Associate Professor at The University of Hong Kong.
Godfrey Chi-Fung Chan, MD, DMD
Scientific Advisor
Tsao Yen-Chow Endowed Professor & Head, Department of Paediatrics & Adolescent Medicine, the University of Hong Kong;
Chief of Service, Department of Paediatrics & Adolescent Medicine, Hong Kong Children's Hospital, HKU-Shenzhen Hospital & Gleneagles Hospital;
Deputy Director, Stem Cells & Regenerative Medicine Consortium;
Chief Commission Service Coordinator (Paediatric Oncology), Hong Kong Children's Hospital. DMD & MD, the University of the East
Prof. Yuk-Lam Lo
Business Advisor
With an outstanding career that spans science, business and innovation, Professor Lo is widely considered the “Father of Biotechnology” in Hong Kong.
Dr. Royce Yuen, JP
Business Advisor
Co-Founder & Co-CEO of MaLogic;
Former Group Chairman, Ogilvy in Hong Kong and Southern China;
Former Council Member of The HK Trade Development Council & The HK Academy for Performing Arts;
Member of the Advisory Committee on Arts Development;
Vetting Committee Member of the SME Development Fund & BUD Fund;
Former Advisory Committee Member for the ICAC, HK Museum, CEDB and the Education Bureau. Vice-Chairman of Plan International (HK);
University Fellowship, the Hong Kong Polytechnic University
Dr. Christopher Corless
Consulting Specialist
Dr. Corless is an expert in applying molecular diagnostics to the classification and prognostication of solid tumors. His work has been published in more than 200 publications. Dr. Corless is currently the Executive Director and Chief Medical Officer at Knight Diagnostics Laboratories in Oregon, USA.
Certifications and Accreditations
HOKLAS ISO 15189 Accreditation; Hong Kong Top Service Brand
- Pangenia Lifesciences Limited meets the requirements of ISO 15189:2012 and it has been accredited for performing specific examinations as listed in the scope of accreditation HOKLAS 862S within the test category of MEDICAL TESTING
- Awarded Hong Kong Top Service Brand 2019
HOKLAS ISO 15189 Accreditation
Hong Kong Top Service Brand 2019
Partner lab –
Knight Diagnostic Laboratories
To complement our in-house expertise, we work closely with KDL to bring oncologists a wide selection of tests. US-based KDL is a global leader in developing genetic tests for solid tumors and hematopoietic malignancies.
College of American Pathologists (CAP) accreditation – Pathology & MP
